Glax­o­SmithK­line trum­pets a PhI­II win in one of Hal Bar­ron's hand­picked drugs, a day af­ter Fi­bro­Gen's face­plant. Will it mat­ter enough to crit­ics?

As Glax­o­SmithK­line CEO Em­ma Walm­s­ley charts a new course ahead of the Big Phar­ma’s planned split while si­mul­ta­ne­ous­ly un­der im­mense pres­sure from ac­tivist in­vestors, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER